National Coverage Determination (NCD)

Tumor Antigen by Immunoassay - CA 125

190.28

Expand All | Collapse All

Tracking Information

Publication Number
100-3
Manual Section Number
190.28
Manual Section Title
Tumor Antigen by Immunoassay - CA 125
Version Number
2
Effective Date of this Version
01/01/2006
Ending Effective Date of this Version
Implementation Date
01/03/2006
Implementation QR Modifier Date

Description Information

Benefit Category
Diagnostic Laboratory Tests


Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Item/Service Description

Immunoassay determinations of the serum levels of certain proteins or carbohydrates serve as tumor markers. When elevated, serum concentration of these markers may reflect tumor size and grade.

This policy specifically addresses tumor antigen CA 125.

Indications and Limitations of Coverage

Indications

CA 125 is a high molecular weight serum tumor marker elevated in 80% of patients who present with epithelial ovarian carcinoma. It is also elevated in carcinomas of the fallopian tube, endometrium, and endocervix. An elevated level may also be associated with the presence of a malignant mesothelioma or primary peritoneal carcinoma.

A CA125 level may be obtained as part of the initial pre-operative work-up for women presenting with a suspicious pelvic mass to be used as a baseline for purposes of post-operative monitoring. Initial declines in CA 125 after initial surgery and/or chemotherapy for ovarian carcinoma are also measured by obtaining three serum levels during the first month post treatment to determine the patient's CA 125 half-life, which has significant prognostic implications.

The CA 125 levels are again obtained at the completion of chemotherapy as an index of residual disease. Surveillance CA125 measurements are generally obtained every 3 months for 2 years, every 6 months for the next 3 years, and yearly thereafter. CA 125 levels are also an important indicator of a patient's response to therapy in the presence of advanced or recurrent disease. In this setting, CA 125 levels may be obtained prior to each treatment cycle.

Limitations

These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient's response to treatment with subsequent treatment cycles.

The CA 125 is specifically not covered for aiding in the differential diagnosis of patients with a pelvic mass as the sensitivity and specificity of the test is not sufficient. In general, a single "tumor marker" will suffice in following a patient with one of these malignancies.

(This NCD last reviewed November 2005)

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Cross Reference

Also see the Medicare Claims Processing Manual Opens in a new window, Chapter 120, Clinical Laboratory Services Based on Negotiated Rulemaking.

Claims Processing Instructions

Transmittal Information

Transmittal Number
47
Revision History

02/2006 - Changes to the Covered Indications for Tumor Antigen by Immunoassay CA 125 to Add Primary Peritoneal Carcinoma. Effective Date: 01/01/2006. Implementation Date: 01/03/2006. (TN 47 Opens in a new window) (CR 4257)

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. (TN 17 Opens in a new window) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02.  Implementation date 1/01/03. (TN AB-02-110 Opens in a new window) (CR 2130)

Other

Covered Code Lists (including narrative)

January 2025 (PDF) (ICD-10 Opens in a new window)
October 2024 (PDF) (ICD-10 Opens in a new window)
July 2024 (PDF) (ICD-10 Opens in a new window)
April 2024 (PDF) (ICD-10 Opens in a new window)
January 2024 (PDF) (ICD-10 Opens in a new window)
October 2023 (PDF) (ICD-10 Opens in a new window)
July 2023 (PDF) (ICD-10 Opens in a new window)
April 2023 (PDF) (ICD-10 Opens in a new window)
January 2023 (PDF) (ICD-10 Opens in a new window)
October 2022 (PDF) (ICD-10 Opens in a new window)
July 2022 (PDF) (ICD-10 Opens in a new window)
April 2022 (PDF) (ICD-10 Opens in a new window)
January 2022 (PDF) (ICD-10 Opens in a new window)
October 2021 (PDF) (ICD-10 Opens in a new window)
July 2021 (PDF) (ICD-10 Opens in a new window)
April 2021 (PDF) (ICD-10 Opens in a new window)
January 2021 (PDF) (ICD-10 Opens in a new window)
October 2020 (PDF) (ICD-10 Opens in a new window)
July 2020 (PDF) (ICD-10 Opens in a new window)
April 2020 (PDF) (ICD-10 Opens in a new window)
January 2020 (PDF) (ICD-10 Opens in a new window)
October 2019 (PDF) (ICD-10 Opens in a new window)
July 2019 (PDF) (ICD-10 Opens in a new window)
April 2019 (PDF) (ICD-10 Opens in a new window)
January 2019 (PDF) (ICD-10 Opens in a new window)
October 2018 (PDF) (ICD-10 Opens in a new window)
July 2018 (PDF) (ICD-10 Opens in a new window)
April 2018 (PDF) (ICD-10 Opens in a new window)
January 2018 (ICD-10 Opens in a new window)
October 2017 (ICD-10 Opens in a new window)
July 2017 (ICD-10 Opens in a new window)
April 2017 (ICD-10 Opens in a new window)
January 2017 (ICD-10 Opens in a new window)
October 2016 (ICD-10 Opens in a new window)
January 2016 (ICD-10 Opens in a new window)
October 2015 (ICD-10 Opens in a new window, ICD-9 Opens in a new window)
October 2014 (ICD-10 Opens in a new window, ICD-9 Opens in a new window)

Changes to Lab NCD Edit Software

January 2025 Opens in a new window
October 2024 Opens in a new window
July 2024 Opens in a new window
January 2024 Opens in a new window
October 2023 Opens in a new window
April 2023 Opens in a new window
January 2023 Opens in a new window
October 2022 Opens in a new window
April 2022 Opens in a new window
January 2022 Opens in a new window
October 2021 Opens in a new window
July 2021 Opens in a new window
October 2020 Opens in a new window
April 2020 Opens in a new window
January 2020 Opens in a new window
October 2019 Opens in a new window
July 2019 Opens in a new window
January 2019 Opens in a new window
October 2018 Opens in a new window
April 2018 Opens in a new window
January 2018 Opens in a new window
July 2017 Opens in a new window
April 2017 Opens in a new window
January 2017 Opens in a new window
January 2016 Opens in a new window
October 2014 Opens in a new window

National Coverage Analyses (NCAs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.

Additional Information

Other Versions
Title Version Effective Between View the document version
Tumor Antigen by Immunoassay - CA 125 2 01/01/2006 - N/A You are here
Tumor Antigen by Immunoassay - CA 125 1 11/25/2002 - 01/01/2006 View
CPT Copyright Statement
CPT only copyright 2002-2011 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
Reasons for Denial
Note: This section has not been negotiated by the Negotiated RuleMaking Committee. It includes CMS’s interpretation of it’s longstanding policies and is included for informational purposes. Tests for screening purposes that are performed in the absense of signs, symptoms, complaints, or personal history of disease or injury are not covered except as explicity authorized by statue. These include exams required by insurance companies, business establishments, government agencies, or other third parties. Tests that are not reasonable and necessary for the diagnosis or treatment of an illness or injury are not covered according to the statue. Failure to provide documentation of the medical necessity of tests may result in denial of claims. The documentation may include notes documenting relevant signs, symptoms, or abnormal findings that substantiate the medical necessity for ordering the tests. In addition, failure to provide independent verification that the test was ordered by the treating physician (or qualified nonphysician practitioner) through documentation in the physician’s office may result in denial. A claim for a test for which there is a national coverage or local medical review policy will be denied as not reasonable and necessary if it is submitted without an ICD-9-CM code or narrative diagnosis listed as covered in the policy unless other medical documentation justifying the necessity is submitted with the claim. If a national or local policy identifies a frequency expectation, a claim for a test that exceeds that expectation may be denied as not reasonable and necessary, unless it is submitted with documentation justifying increased frequency. Tests that are not ordered by a treating physician or other qualified treating nonphysician practitioner acting within the scope of their license and in compliance with Medicare requirements will be denied as not reasonable and necessary. Failure of the laboratory performing the test to have the appropriate Clinical Laboratory Improvement Act of 1988 (CLIA) certificate for the testing performed will result in denial of claims.